

FORM 7

**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **Global Cannabis Applications Corp. (the "Issuer")**

Trading Symbol: **APP**

Number of Outstanding Listed Securities: **154,765,796 (as at November 30, 2020)**

Date: **December 1, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

***The Issuer is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world's first end-to-end – from patient to regulator – medical cannabis data solution. It uses core technologies: mobile applications, artificial intelligence, regtech, smart databases, and blockchain, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, the Issuer is focused on viral global expansion by providing the best digital experience in the cannabis market.***

**During the month of November 2020, the Issuer continued with general and corporate operations with no changes to material activities.**

2. Provide a general overview and discussion of the activities of management.

**During the month of November 2020, management continued to support and control the Issuer's business activities with a focus on creating broader awareness of the Issuer and continued development of product line.**

**In addition:**

**On November 10, 2020 the company announced that it entered into Definitive Agreement with Purity-IQ Biotechnology Vancouver, British Columbia, Canada, a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Definitive Agreement ("Agreement") with Canadian company Purity-IQ Inc. ("Purity-IQ") to commercially integrate the Purity-IQ Cannabis Authenticity and Purity Standard (CAPS) into the GCAC platform; with a focus on the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA\$4.1 billion in 2021. This Agreement expands the GCAC Cultivator-SaaS license to allow cultivators to pay a "Purity-IQ Access Fee" to GCAC. The access fee enables the immutable connection of a medical cannabis strain' batch to a Purity-IQ ISO17025 certified laboratory test result. These results are then further attested-to using GCAC's chain of custody blockchain platform, thereby ensuring product quality and consistency of strain and dosage, for the consumer or patient. Purity-IQ and its patented process uniquely fingerprints cultivars based on a metabolite profile using Nuclear Magnetic Resonance (NMR) and DNA chip bioinformatics. Fingerprints are then referenced by GCAC's efficacy platform to verify batch-to-batch consistency in medical cannabis efficacy programs. GCAC's CEO, Brad Moore "We're continuing to bring more truth to the medical cannabis space. Being able to compare the efficacy of a cultivator's cannabis strain on a batch-by-batch basis offers consumers products that they can trust. These disclosures also help pharmacies and dispensaries to build and protect their brands. Commercially, cultivators pay our access fee to link Purity-IQ batch-to-batch attestations to a crop, then this, in turn, brings other parts of the value chain into the GCAC fold, as they opt to work with growers committed to transparency." Paul Valder, Cofounder and Chief Technology Officer at Purity-IQ commented "CAPS identifies and differentiates medical cannabis products, builds intellectual brand property and ensures authenticity. GCAC supports the whole value chain, including the Purity-IQ testing phases, and gives consumers full transparency, trust and confidence in the products they consume." Under the Agreement, all GCAC derived attestation data is the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with GCAC's medical cannabis datasets and solutions. The company believes this makes GCAC one of the most complete, and exciting, efficacy platforms in the cannabis and RegTech space.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None to report during the month of November 2020.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None to report during the month of November 2020.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None to report during the month of November 2020.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None to report during the month of November 2020.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None to report during the month of November 2020.**

8. Describe the acquisition of new customers or loss of customers.

**None to report during the month of November 2020.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None to report during the month of November 2020.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None to report during the month of November 2020.**

11. Report on any labour disputes and resolutions of those disputes, if applicable.

**None to report during the month of November 2020.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None to report during the month of November 2020.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None to report during the month of November 2020.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common shares (financing)	Nil	N/a	Not applicable
Common shares (debt settlement)	Nil	N/a	Not applicable
Common share purchase warrants	Nil	N/a	Not applicable
Stock options	8,950,000	Stock options granted November 16, 2020, each exercisable at \$0.10 with an expiry date of November 16, 2025	Not applicable

(1) State aggregate proceeds and intended allocation of proceeds

15. Provide details of any loans to or by Related Persons.

**None to report during the month of November 2020.**

16. Provide details of any changes in directors, officers or committee members.

**None to report during the month of November 2020.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Trends and risks, which may impact the Issuer, are detailed in Item 17, Risk Factors, of the Issuer's Form 2A – Listing Statement dated October 16, 2014.**

**THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.**

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 1, 2020

Bradley Moore

Name of Director or Senior Officer

/s/ Bradley Moore

Signature

Chief Executive Officer, Director

Official Capacity

Issuer Details Name of Issuer Global Cannabis Applications Corp.	For Month End November 30 2020	Date of Report YY/MM/DD 20/12/01
Issuer Address Suite 830, 1100 Melville Street Vancouver, BC V6E 4A6	Issuer Fax No. N/A	Issuer Telephone No. (855) 269-9554
Contact Name Bradley Moore	Contact Position CEO, Director	Contact Telephone No. (855) 269-9554
Contact Email Address info@cannappscorp.com	Web Site Address www.cannappscorp.com	